Who is sponsoring NCT02047630?

NCT02047630 is sponsored by CHU de Quebec-Universite Laval.

What condition does NCT02047630 study?

NCT02047630 studies Primary Open Angle Glaucoma, Ocular Hypertension.

What drugs are being tested in NCT02047630?

Interventions: Generic latanoprost, Brand-name latanoprost.

What is the status of NCT02047630?

NCT02047630 is currently TERMINATED.

Last reviewed 2017-07-23 · How we verify

Efficacy of the Brand-name Latanoprost and One of Its Generic Version in Primary Open Angle Glaucoma and Ocular Hypertension

NCT02047630 Phase 4 TERMINATED

The purpose of this study is to evaluate and compare efficacy and tolerability of the brand-name latanoprost and one of its generic version in subjects with primary open angle glaucoma or ocular hypertension. This randomized, double-blinded, cross-over design study has a 4 months follow-up. There are two periods of 8 weeks. During the first period, subjects put brand-name latanoprost in one eye and the generic version in the other one. In the second period, drops are switched from one eye to the other. There are intraocular pressure measurements (diurnal curves) on day 0 (before treatment), at 8 weeks (at the end of first period) and at 16 weeks (at the end of second period). Variations of intraocular pressure in each eye will be evaluated.

Details

Lead sponsor	CHU de Quebec-Universite Laval
Phase	Phase 4
Status	TERMINATED
Enrolment	60
Start date	2014-01
Completion	2014-12-04

Conditions

Primary Open Angle Glaucoma
Ocular Hypertension

Interventions

Generic latanoprost
Brand-name latanoprost

Primary outcomes

Change in Intraocular Pressure (IOP) — 8 weeks, 16 weeks
Goldman applanation tonometry will be used to measure IOP.

Countries

Canada